Figure 2 | Experimental & Molecular Medicine

Figure 2

From: ANT2 shRNA downregulates miR-19a and miR-96 through the PI3K/Akt pathway and suppresses tumor growth in hepatocellular carcinoma cells

Figure 2

miR-19a and miR-96 enhance proliferation and tumorigenicity of hepatocellular carcinoma (HCC) in vitro. (a) HepG2 and Hep3B liver cancer cells were transfected with miR-19a mimics, miR-96 mimics, miR-19a inhibitors and miR-96 inhibitors. Cell viability (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)) assays were performed 1, 2, 3 and 7 days after transfection. (b) Soft agar colony formation assays were conducted after HepG2 cells were transfected with miR-19a mimics, miR-96 mimics, miR-19a inhibitors and miR-96 inhibitors. Three independent experiments were performed. The mean±s.d. is shown, and data were analyzed using Student’s t-test.

Back to article page